Evidence map›Paper›PMID 40355586›Full record

ArticleScientific reports2025

Tumor microenvironment modulation by SERPINE1 increases radioimmunotherapy in murine model of gastric cancer.

Javeria Zaheer, Joycie Shanmugiah, Seungyoun Kim, Hyeongi Kim, Jin Su Kim

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Current Status of Research on Losartan in Tumour Therapy.Journal of cellular and molecular medicine · 2026
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Javeria ZaheerDivision of Applied RI, Korea Institute of Radiological and Medical Sciences, 75 Nowon-Ro, Nowon-Gu, Seoul, 01812, Republic of Korea.
Joycie ShanmugiahDivision of Applied RI, Korea Institute of Radiological and Medical Sciences, 75 Nowon-Ro, Nowon-Gu, Seoul, 01812, Republic of Korea.
Seungyoun KimDivision of Applied RI, Korea Institute of Radiological and Medical Sciences, 75 Nowon-Ro, Nowon-Gu, Seoul, 01812, Republic of Korea.
Hyeongi KimDivision of Applied RI, Korea Institute of Radiological and Medical Sciences, 75 Nowon-Ro, Nowon-Gu, Seoul, 01812, Republic of Korea.
Jin Su KimDivision of Applied RI, Korea Institute of Radiological and Medical Sciences, 75 Nowon-Ro, Nowon-Gu, Seoul, 01812, Republic of Korea. kjs@kirams.re.kr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An elevated extracellular matrix (ECM) and interstitial fluid pressure (IFP) in gastric cancer limits the targeting of HER2-expressing cells when radioimmunotherapy (RIT) with

Indexed as

Plasminogen Activator Inhibitor 1RadioimmunotherapyStomach NeoplasmsTumor MicroenvironmentAnimalsCell Line, TumorDisease Models, AnimalExtracellular MatrixFemaleGene Expression Regulation, NeoplasticHumansLosartanMatrix Metalloproteinase 2MiceTrastuzumabLosartanMatrix Metalloproteinase 2Plasminogen Activator Inhibitor 1Trastuzumab64CuExtracellular matrixLosartanRadioimmunotherapySERPINE1Trastuzumab

Identifiers

PMID40355586
PMCPMC12069594

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.